ERBB3 and neoplasm: The blockade of EGFR and HER3 combined with drugs results in superior anti-tumor activity in vitro and in vivo, suggesting the importance of inhibition on both the upstream activation of key molecules and the downstream signaling pathway, due to the cellular response of activating an alternative pathway for cancer cell survival.